Crossref
FDA Okays First Drug for Scarring From Fatty Liver Disease
JAMA · 2024
DOI: 10.1001/jama.2024.5154 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Drug Approval, Non-alcoholic Fatty Liver Disease, Anti-Inflammatory Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Drug ApprovalNon-alcoholic Fatty Liver DiseaseAnti-Inflammatory AgentsHumansCicatrixUnited StatesUnited States Food and Drug AdministrationLiver CirrhosisReceptors, Thyroid Hormone
Substanzen
Anti-Inflammatory AgentsReceptors, Thyroid Hormone
Zitieren
APA
Harris, E. (2024). FDA Okays First Drug for Scarring From Fatty Liver Disease. JAMA. https://doi.org/10.1001/jama.2024.5154
Vancouver
Harris E. FDA Okays First Drug for Scarring From Fatty Liver Disease. JAMA. 2024. doi:10.1001/jama.2024.5154
BibTeX
@article{Harris2024,
author = {Harris, Emily},
title = {FDA Okays First Drug for Scarring From Fatty Liver Disease},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.5154}
}
EUVIMED